Printer Friendly

JACOBS WINS CONTRACT WITH NOVO NORDISK PHARMACEUTICAL INDUSTRIES INC.

JACOBS WINS CONTRACT WITH NOVO NORDISK PHARMACEUTICAL INDUSTRIES INC.
 SOMERSET, N.J., June 17 /PRNewswire/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that its Triad Technologies Inc. subsidiary received a contract to perform qualification/validation services for Novo Nordisk Pharmaceutical Industries Inc. (NNPII) at its plant currently under construction in Clayton, N.C.
 Triad began in December 1991 and expects to be completed at the end of 1992 with startup planned for 1993. Triad is currently doing overall site project management and scheduling of the validation effort for four firms including NNPII. Prior to the award of this contract, Triad performed the validation master planning.
 Novo Nordisk is a major force in insulin production and diabetes care worldwide and is the world's largest producer of industrial enzymes. The company also manufacturers and markets a variety of other pharmaceutical and bioindustrial products. Headquartered in Denmark, NNPII employs more than 9,500 people in more than 30 countries and markets its products in 120 countries.
 Jacobs Engineering Group, headquartered in Pasadena, Calif., provides single-source consulting, engineering, design, architectural, environmental and hazardous waste management, procurement, construction, construction management, contract maintenance and operations services to government and industry worldwide. Jacobs has 22 offices located throughout the United States and Ireland.
 -0- 6/17/92
 /CONTACT: Stefanie Spikell of Jacobs Engineering Group, 818-578-6835/
 (JEC) CO: Jacobs Engineering Group Inc.; Triad Technologies; Novo Nordisk
 Pharmaceutical Industries Inc. ST: California, North Carolina IN: CST MTC SU: CON


EH-JL -- LA001 -- 0928 06/17/92 08:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1992
Words:250
Previous Article:QUIDEL RECEIVES U.S PATENT WHICH WILL EXPAND ITS FERTILITY FRANCHISE
Next Article:NADIA COMANECI SIGNS WITH SPORTS STEP
Topics:


Related Articles
ANERGEN AND NOVO NORDISK ENTER INTO MULTIPRODUCT COLLABORATION
INCYTE PHARMACEUTICALS AND NOVO NORDISK ANNOUNCE GENE DATABASE ACCESS AGREEMENT
NOVO NORDISK AND RHONE-POULENC RORER FORM WORLDWIDE STRATEGIC ALLIANCE TO OFFER COMPREHENSIVE RANGE OF HORMONE REPLACEMENT THERAPIES
RHONE-POULENC RORER AND NOVO NORDISK FORM WORLDWIDE STRATEGIC ALLIANCE TO OFFER COMPREHENSIVE RANGE OF HORMONE REPLACEMENT THERAPIES
RHONE-POULENC RORER AND NOVO NORDISK FORM WORLDWIDE STRATEGIC ALLIANCE TO OFFER COMPREHENSIVE RANGE OF HORMONE REPLACEMENT THERAPIES
Novo Nordisk Signs Research Agreement with Ontogen
Novo Nordisk in Research Collaboration With Takeda
Boron, LePore & Associates, Inc. Signs Three-Year Agreement with Novo Nordisk Pharmaceuticals, Inc.
Novo Nordisk and Bedford Laboratories, a Division of Ben Venue Laboratories, Announce U.S. Marketing Deal for GlucaGen(R).
Novo Nordisk Pharmaceuticals, Inc., Awarded Novation Contract.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters